Medication Guide App

Label Changes for:

Lumizyme (alglucosidase alfa)

May 2014

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

  

May 2014

6 ADVERSE REACTIONS

6.3 Postmarketing Experience...section updated

 

July 2012

ADVERSE REACTIONS

Postmarketing Experience
  • abdominal pain, nephrotic syndrome and proteinuria, as observed events to the package insert

 

Hide
(web5)